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ABSTRACT
The intention of this review on nevus
comedonicus (NC) is to update on clinical
features, pathogenesis, and therapy. NC is a
rare epidermal nevus type. It is part of the nevus
comedonicus syndrome, a neurocutaneous
disorder with ocular, skeletal, and central
nervous symptoms. Recently, acne-related
signaling pathways and somatic mutations of
tyrosine kinase receptors have been identified
and may play a role in NC pathogenesis. On
preexistent NC secondary skin tumors can
develop, which are often benign. Treatment
options of NC include topical therapy, laser,
and surgery.
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INTRODUCTION
Nevus comedonicus (NC) is a rare skin disorder.
In this review, we will provide an update on
clinical features, pathogenesis, and treatment
options.
Clinically NC is characterized by closely
arranged, dilated follicular openings with
keratinous plugs resembling classical
comedones. It is a rare type of an epidermal
nevus usually with predilection for the face and
neck area [1]. The disease was first described in
1895 by Kofmann [2] who suggested the term
‘comedo nevus’.
NC can occur congenitally or develop later
in life, most commonly at the age of
approximately 10 years. NC is part of the
nevus comedonicus syndrome (NCS), a term
coined by Engber in 1978 [1, 3].
Epidemiology
The prevalence of NC has been estimated from
1 in 45,000 to 1 in 100,000, with no gender or
racial preference [1, 3]. In 50% of patients, the
condition develops shortly after birth and in the
majority of patients lesions appear before the
age of 10 [4–6]. Single cases of delayed
development of NC and NCS at later age have
been reported [4–6].
Clinical Characteristics
NC is usually asymptomatic and most
commonly it affects the face and neck area
and, by exception, other anatomical regions,
including genital area, palms, and soles.
Clinically, NC presents with grouped, dilated,
plugged follicular ostia in a honeycomb pattern.
The plugged ostia contain lamellated
keratinaceous material. Their appearance
resembles black dots but the material cannot
be easily removed mechanically in contrast to
acne comedones [1, 7].
NC lesions might present with various
patterns of distribution: unilateral, bilateral,
linear, interrupted, segmental, or blaschkoid
(Figs. 1, 2 and 3) [3].
Two types of NC have been identified;
the first is non-pyogenic NC with acne-like
characteristics and a second type characterized
by formation of cysts, papules, pustules, and
abscesses in various stages of development
[8, 9]. The former type is also known as
Munro’s acne nevus and separated by some
authors from NC [3]. Differential diagnoses are
shown in Table 1.
Histopathology
The major histopathologic symptoms are large
grouped, dilated follicular ostia devoid of hair
shafts but filled with keratin layers (Fig. 4). At
some locations in the bases of the follicular
invaginations one may observe singular
rudimentary glands, which are not, however,
obligatory as they may be absent. Small
cysts, cystic invaginations, and occasionally
large cysts may be seen in histopathologic
investigation; the variable cystic structures
Fig. 1 Nevus comedonicus: plaque-like lesion with wide
open follicles on the neck (44-year-old Caucasian male)
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are lined by keratinizing squamous
epithelium [1, 7]. Hyperkeratosis (epidermolytic
hyperkeratosis) and acanthosis of the epidermis
may be present but not para- or dyskeratosis
[8, 10–13].
An increased number of Langerhans cells had
been observed by electron microscopy [11]. More
abundant tonofilaments in the upper part of the
stratum spinosum and numerous keratohyalin
granules were also noticed [11, 12]. The arrector
pili muscles were incompletely differentiated
and demonstrated intracellular glycogen
particles [11, 12].
Fig. 2 Stages of treatment of a 29-year-old Asian male with
linear nevus comedonicus of the leg with multiple follicular
openings. a Presentation of linear nevus comedonicus with
multiple follicular openings. b Surgical excision. c Three
weeks after surgical excision. d With compression garment
to avoid postsurgical lymphedema
Fig. 3 Nevus comedonicus of the neckwith pseudoepithelial
epidermal hyperplasia in a 39-year-old Caucasian
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Cytokeratin expression in NC is comparable
to that in normal skin [14]. Filaggrin, which is
usually located in the granular epidermal layer,
occurs in the whole epidermis of closed
comedones suggesting its role in their
development [14, 15].
Interaction between fibroblast growth factor
(FGF) and FGF receptor-2 (FGFR2) is a crucial
pathway for mesenchymal–epithelial interplay
in pilosebaceous unit development. FGFR is a
family of tyrosine kinase receptors. FGFR2b is
exclusively found in epithelial cells including
epidermal keratinocytes and sebocytes [15, 16].
Overstimulation of FGFR2 signaling with
increased expression of interleukin-1a may
be involved in NC pathogenesis. Somatic
mutations like Ser252Trp substation have been
identified in individual patients with segmental
acne [16–18].
c-Secretase found in human hair follicle
epithelium is another candidate for NC since
the absence of this enzyme results in complete
conversion of hair follicles to epidermal cysts
[19].
Association with Genetic Syndromes
and Other Diseases
NCS (ORPHA64754) belongs to the group of
epidermal nevus syndromes including
Schimmelpenning syndrome, phacomatosis
pigmentokeratotica, angora hair nevus
syndrome, and Becker nevus syndrome among
others where a genetic basis has yet not been
identified [3, 4, 20].
NCS is a neurocutaneous disorder which
consists of NC with skeletal, ocular, and
central nervous system abnormalities. The
most common symptoms include cataracts,
scoliosis, fused vertebrae, spina bifida, and
delayed mental development [5, 6]. In
addition, seizures, paresis, dysgenesis of
corpus callosum, electroencephalographic
abnormalities, limb deformities such as
absence of the fifth finger, polysyndactyly or
clinodactyly, oligodontia, and other skin
disorders such as ichthyosis, leukoderma,
lichen striatus, linear morphea, Sturge-Weber
syndrome, hemangiomas, and inverse acne
have been reported in NCS [1, 3, 4, 20–22].
NCS is associated with epithelial tumors
such as trichoepithelioma, pilar sheath tumor
or dilated pore of Winer, keratoacanthoma,
syringocystadenoma papilliferum, hidradenoma
papilliferum, and very rarely basal cell carcinoma
or squamous cell carcinoma [23–26].
Fig. 4 Histopathology of nevus comedonicus. a Overview
(hematoxylin and eosin stain [HE] 9 2). b Details with
large follicles containing lamellated keratin but absent hair
shafts (HE 9 4)
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TREATMENT
Being benign, NC does not require aggressive
treatment, except for aesthetic reasons or in
complicated cases. Conservative options
include emollients and moisturizer, topical
corticosteroids (for inflammatory lesions),
keratolytics such as salicylic acid, or 12%
ammonium lactate solution. Conservative
treatment may improve cosmesis in some
patients [27, 28].
Since retinoids are working in acne, they
have also been used in NC. Achievements with
topical tretinoin are limited. Some reports
showed better improvement of NC by topical
tazarotene as monotherapy or in combination
with topical mometasone furoate or
calcipotriene [29–31]. No complete resolution
can be achieved by this and relapses are
common.
Oral retinoids, such as isotretinoin, were
found to be ineffective in most cases but may
be an option in widespread systematized
inflammatory variants [32, 33]. There have, as
yet, been no published studies of other
retinoids, such as topical adapalene and
systemic or topical bexarotene.
Of potential interest are FGFR inhibitors
with antivascular activity [34]. Interleukin-1a
inhibitors can be classified into receptor
inhibitors, such as anakinra, and monoclonal
antibodies against the interleukin itself
[35]. Currently, there are no data available for
NC.
Another interesting drug target is c-secretase;
stimulators of this enzyme such as general
control nonderepressible 2 (GCN2)—a subunit
of eukaryotic translation factor 2 kinase—might
be a future therapeutic option [36].
Localized NC can be removed by surgical
excision with good aesthetic results in contrast
to superficial shaving, comedo extraction, and
dermabrasion techniques (Fig. 2a–d) [37]. If linear
NC is surgically removed on the limbs, complex
decongestive therapy including manual lymph
drainage and compression garments supports the
healing process (Fig. 2d). Larger lesions may need
transplantation for defect closure, or another
option is the use of repeat-filling or self-filling
osmotic tissue expanders to obtain a resurplus of
skin for defect closure [38, 39].
Laser treatments with 2,940-nm erbium YAG,
10,600-nm ultrapulsed CO2, or 1,450-nm diode
lasers have shown improvement in single patients
[40–42]. Skindepressionwillhoweverstay. Erbium
YAG laser treatment is often followed by delayed
relapses. In contrast to ablative lasers, the
1,450 nm diode shrinks sebaceous glands and
reduces seborrhea. The combination of 1,450-nm
diode laser with 1,550-nm erbium-doped fiber
laser has potential for treating NC [43].
CONCLUSION
With this review we provided an update on
clinical features, pathogenesis and treatment
option of NC. NC is a rare epidermal nevus.
Diagnosis is based on clinical examination and
histopathology. New data are available on
signaling pathways in acne-related disorders
that may have an impact on NC as well. In
contrast to the acne-related comedones, the
epithelium is often hyperkeratotic and
sometimes acanthotic and comedo extraction
is not as easily achieved as with acne
comedones. Dermatologists should be aware of
potential association of NC with skin tumors
and extracutaneous findings such as NCS. The
most effective treatment available is complete
surgical excision. New developments in laser
technology may become an alternative in near
future. With a more detailed understanding in
molecular pathogenesis, targeted therapy will
become a future perspective.
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